Navigation Links
Peloton Therapeutics Completes $18 Million Series A Financing
Date:7/27/2011

DALLAS, July 27, 2011 /PRNewswire/ -- Peloton Therapeutics, Inc., an early-stage cancer drug discovery and development company, has announced the completion of an $18 million Series A financing.  Led by The Column Group and joined by Remeditex Ventures and Peter O'Donnell, Jr., the Series A funds supplement a recently awarded $11 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

Peloton officials said the company will focus initially on advancing several well differentiated oncology programs, each of which has already yielded promising lead compounds with novel mechanisms of action. Peloton leveraged its close relationship with the University of Texas Southwestern Medical Center to in-license these programs, providing a kick-start to its internal research and development capabilities. Peloton's goal is to become a leading oncology company generating a sustainable pipeline of cancer therapies that are designed to enhance outcomes and treatment practices.  

The Company was founded by renowned scientist Steven L. McKnight, Ph.D., who is recognized as one of the world leaders in gene regulation based in part on his discovery of leucine zipper proteins. Dr. McKnight is Chairman of Biochemistry at UT Southwestern and holds the Distinguished Chair in Basic Biomedical Research and the Sam G. Winstead and F. Andrew Bell Distinguished Chair in Biochemistry. The high-throughput screening laboratory Dr. McKnight built at the medical center over the past decade has seeded the Peloton pipeline with a number of attractive compounds that are well positioned for lead optimization.

"Peloton has the potential to emerge as a top-notch cancer company, distinguished by its scientific rigor, drug discovery capabilities, and talented team," Dr. McKnight said. "Peloton is off to a strong start in advancing its therapeutic programs quickly and effectively."

Peloton's Board of Directors includes Nobel Laureate Michael S.
'/>"/>

SOURCE Peloton Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
2. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
3. Oxygen Healthcare (O2h) Announces Expanded Chemistry Collaboration With Heptares Therapeutics
4. Dr. Andrew Scharenberg, M.D., to Serve as Chief Scientific Officer for Cellectis therapeutics
5. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
6. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
7. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
8. Sorrento Therapeutics Innovative Approach to Developing Vaccines and Therapeutics for MRSA Receives Continued Support From the National Institute of Allergy and Infectious Diseases
9. Amicus Therapeutics Joins Russell 3000® Index
10. Nile Therapeutics Provides Update on Ongoing Phase I Clinical Trial of Cenderitide
11. Nile Therapeutics, Inc. Completes $2.5 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Los Angeles (PRWEB) August 22, 2014 ... for age-defying products, is in the spotlight again. ... night cream and its NeriumFirmTM Body Contouring Cream ... presented by Backstage Creations during the 66th Primetime ... the patented NAE-8® extract, third-party clinical trials show ...
(Date:8/21/2014)... 2014  BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX ® ... and XIAPEX ® in the EU, today ... double-blind Phase 2a study of CCH for the ... The results showed that all three doses of ...
(Date:8/21/2014)... international research team including DESY scientists has observed tiny ... team reports in the journal Science that ... inside the nanodroplets. It is the first time that ... larger samples of what is known as superfluid helium, ... our best expectations," says Andrey Vilesov of the University ...
(Date:8/21/2014)... IA (PRWEB) August 21, 2014 His ... LIBERTY Opening , The Court of His Majesty Willem-Alexander, ... will attend the Grand Opening of POET-DSM Advanced Biofuels’ ... Wednesday, Sept. 3. , The King will take part ... opening activity, scheduled for 11 a.m.-12:20 p.m. and tour ...
Breaking Biology Technology:Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Scientists observe quantum vortices in cold helium droplets 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3
... 19 MAKO Surgical,Corp. today announced that it has filed ... Exchange Commission relating to a proposed,initial public offering of its ... sold by MAKO Surgical Corp. The,number of shares to be ... been determined. The Company intends to apply to have its ...
... AMSTERDAM, September 19 - IDF Launches ... IDF today issued the new global guideline ... glucose.(1) The guideline emphasizes,that people with diabetes should ... in order to optimize diabetes control and reduce ...
... BASEL, Switzerland, September 19 ,Arpida Ltd (SWX: ARPN) ... summary session of new antimicrobial agents at the ... (ICAAC) in,Chicago. ICAAC is a major scientific conference ... the world gather to discuss the,latest developments in ...
Cached Biology Technology:MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock 2The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes 2The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes 3Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 3
(Date:8/21/2014)... of American singles found that during sex with ... rates. On average, men experience orgasm 85.1 percent ... little difference. For women, however, orgasm occurrence is ... percent of the time during sex with a ... women,s sexual orientation, with lesbian women experiencing orgasm ...
(Date:8/21/2014)... a previously unknown process for harvesting energy and producing ... Penn State University scientist has discovered. The discovery lays ... growth, harvesting energy from the Sun, and understanding dense ... other lakes worldwide. A paper describing the discovery will ... of the journal Science on 21 August ...
(Date:8/21/2014)... ubiquitous skin fungus linked to dandruff, eczema and other ... to even further global reachesincluding Hawaiian coral reefs and ... vents. , A review in the scientific journal ... of the fungi of the genus Malassezia ... sequencing datasets from around the world. , University of ...
Breaking Biology News(10 mins):Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2
... South Korea, Jan. 8 Pixelplus Co.,Ltd. ... company in Korea that designs,develops, and markets ... today announced that it unveiled the "PM1002", ... image recognition,applications., The PM1002 integrates a ...
... 8, 2008) Adolescent girls who frequently eat meals ... pills, laxatives, or other extreme measures to control their ... Dianne Neumark-Sztainer, Ph.D., M.P.H., R.D., lead investigator of Project ... Minnesota School of Public Health. Neumark-Sztainer and Project ...
... Philadelphia, PA, January 8, 2008 Schizophrenia is a ... increased risk. Available antipsychotic medications treat some of ... only a subset of patients. Unfortunately, it is ... in any given individual with schizophrenia. John H. ...
Cached Biology News:Pixelplus Unveils Its PM1002 as A Practical Biometric Solution for Iris, Facial and Fingerprint Recognition 2Pixelplus Unveils Its PM1002 as A Practical Biometric Solution for Iris, Facial and Fingerprint Recognition 3U of M research finds disordered eating less common among teen girls who regularly eat family meals 2Genetic variant predicts antipsychotic response for schizophrenia patients by ethnicity 2
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
... Mucin 3 (MUC3) is a glycoprotein. ... a lesser extent in breast, lung and ... shows no cross-reaction with MUC1 and MUC2. ... human MUC3 Immunogen: MUC3 tandem ...
... CDX2, a member of the caudal-related ... that regulates both proliferation and differentiation in ... role in triggering cells towards the phenotype ... in the maintenance of the phenotype. Clone ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Biology Products: